KRAS-mutant CRC is associated with immunologically “cold” tumors and resistance to ICB therapy in CRC patients.36 Mutant KRAS-mediated MDSC recruitment is an obstacle to ICB therapy effectiveness by suppressing an effective antitumor cytotoxic T-cell response. The gene discussed is KRAS; the disease is colorectal carcinoma.